Literature DB >> 23895136

Drug targets for rational design against emerging coronaviruses.

Qi Zhao1, Erin Weber, Haitao Yang.   

Abstract

The recent, fatal outbreak of the novel coronavirus strain in the Middle East highlights the real threat posed by this unique virus family. Neither pharmaceutical cures nor preventive vaccines are clinically available to fight against coronavirus associated syndromes, not to mention a lack of symptom soothing drugs. Development of treatment options is complicated by the unpredictable, recurring instances of cross-species viral transmission. The vastly distributing virus reservoir and the rapid rate of host-species exchange of coronavirus demands wide spectrum potency in an ideal therapeutic. Through summarizing the available information and progress in coronavirus research, this review provides a systematic assessment of the potential wide-spectrum features on the most popular drug targets including viral proteases, spike protein, RNA polymerases and editing enzymes as well as host-virus interaction pathways associated with coronaviruses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23895136     DOI: 10.2174/18715265113139990024

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  3 in total

1.  Resveratrol inhibits enterovirus 71 replication and pro-inflammatory cytokine secretion in rhabdosarcoma cells through blocking IKKs/NF-κB signaling pathway.

Authors:  Li Zhang; Yuanyuan Li; Zhiwen Gu; Yuyue Wang; Mei Shi; Yun Ji; Jing Sun; Xiaopeng Xu; Lirong Zhang; Jingtin Jiang; Weifeng Shi
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

Review 2.  Recent progress in the discovery of inhibitors targeting coronavirus proteases.

Authors:  Haofeng Wang; Song Xue; Haitao Yang; Cheng Chen
Journal:  Virol Sin       Date:  2016-02-19       Impact factor: 4.327

Review 3.  The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.

Authors:  Rachael S Felberbaum
Journal:  Biotechnol J       Date:  2015-03-20       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.